Biology subjects

Antoniou, S.

Publications and source records attributed to Antoniou, S..

3 recordsLinked to original sources

bioRxiv2026

Ubiquitinome dynamics and regulation by DUB2 during Leishmania differentiation

Leishmaniasis is caused by Leishmania parasites, which undergo cellular adaptation when transitioning from the insect stage (promastigote) to the mammalian stage (amastigote). While the ubiquitin-proteasome system (UPS) is vital for life cycle progression, global ubiquitination dynamics have remained unmapped. We established a quantitative ubiquitinomics workflow for Leishmania mexicana, identifying over 9,100 ubiquitination sites across 38% of the proteome, revealing thousands of stage-specific regulatory events. Promastigote-enriched sites associate with cell motility, while amastigote-enriched sites link to metabolism and glycosome organization. We identified extensive ubiquitination on UPS components, including the essential virulence factor deubiquitinase 2 (DUB2). Using inducible gene deletion and XL-BioID proximitomics, we identified 111 potential DUB2 substrates. High-confidence substrates include the E2 conjugating enzyme UBC2, which is required for differentiation, and SUMO, a critical regulator of ubiquitin crosstalk. The discovery of UBC2 as a substrate of DUB2 directly links ubiquitination with promastigote to amastigote differentiation. Our findings provide a comprehensive map of the Leishmania ubiquitinome and demonstrate that DUB2 acts as a pleiotropic regulator controlling post-translational modifications of essential proteins involved in life cycle progression.

microbiology↗

bioRxiv2025

Resolving hematopoietic stem versus progenitor cell potential in the mouse dorsal aorta by differential Runx1 +110 enhancer activity

Hematopoietic stem cells (HSCs) are important in cell-based therapies for blood-related disorders. While progress has been made in the directed differentiation of pluripotent PSCs, such cultures promote hematopoietic progenitor cells (HPCs) over HSCs. Thus, elucidating signals, factors, and markers associated with HSC versus HPC lineage development in the embryo is imperative. During mouse embryonic development, HSCs and HPCs originate from hemogenic endothelium (HE) through a process critically dependent on the transcription factor Runx1. Here, we identified a Runx1 enhancer that distinguishes emerging dorsal aorta HSCs from HPCs. Phenotypic, functional, and transcriptomic analyses of Runx1 +110 enhancer-GFP reporter (110GFP) transgenic embryos showed that 110GFP expression marks HPCs, but not the emerging HSC lineage. Comparative transcriptomics revealed a 17-gene signature associated with in vivo long-term HSC potential. Furthermore, 110GFP- preHSCs showed increased expression of Jarid2 and other PRC2 components, suggesting a role for epigenetic regulation in establishing the HSC fate during EHT. Finally, single-cell multiome analysis of dorsal aorta EHT identified the Runx1 +3 enhancer as preferentially accessible in preHSC and underlined the specific activity of the +110 enhancer in HPCs. Our study demonstrates the power of cell-type specific enhancer-reporter models to dissect cell fate decisions in development and provides new inroads to label and/or perturb HSC versus HPC fate decisions in vivo and in vitro.

developmental biology↗

bioRxiv2019

Immune surveillance in clinical regression of pre-invasive squamous cell lung cancer

Before squamous cell lung cancer develops, pre-cancerous lesions can be found in the airways. From longitudinal monitoring, we know that only half of such lesions become cancer, whereas a third spontaneously regress. While recent studies have described the presence of an active immune response in high-grade lesions, the mechanisms underpinning clinical regression of pre-cancerous lesions remain unknown. Here, we show that host immune surveillance is strongly implicated in lesion regression. Using bronchoscopic biopsies from human subjects, we find that regressive carcinoma in-situ lesions harbour more infiltrating immune cells than those that progress to cancer. Moreover, molecular profiling of these lesions identifies potential immune escape mechanisms specifically in those that progress to cancer: antigen presentation is impaired by genomic and epigenetic changes, TGF-beta signalling is overactive, and the immunomodulator TNFSF9 is downregulated. Changes appear intrinsic to the CIS lesions as the adjacent stroma of progressive and regressive lesions are transcriptomically similar. This study identifies mechanisms by which pre-cancerous lesions evade immune detection during the earliest stages of carcinogenesis and forms a basis for new therapeutic strategies that treat or prevent early stage lung cancer.

cancer biology↗